Publications by authors named "Compter A"

Background And Purpose: Treatment modalities for patients with brain metastases consist of surgery, radiotherapy, and systemic treatments such as immunotherapy and targeted therapy. Although much is known about local control of brain metastases after radiotherapy and surgery alone, more understanding is needed of the additional effect of new systemic treatments. Our study presents real-world data about the combined effects of different local and systemic treatment strategies on local response of irradiated brain metastases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the challenges of diagnosing and treating leptomeningeal metastases (LM) in patients with EGFR mutation positive non-small cell lung cancer (NSCLC) who are being treated with osimertinib, focusing on identifying resistance mechanisms in cerebrospinal fluid (CSF) and plasma.
  • A group of 28 patients was analyzed, with a high detection rate of the driver mutation in CSF, but resistance mechanisms were found in 27%, indicating limitations in treatment options available at this time.
  • After four weeks on an escalated osimertinib dosage, many patients showed stabilization or worsening of symptoms, suggesting that while some had radiological improvement, overall clinical efficacy remains
View Article and Find Full Text PDF

Whole brain radiotherapy (WBRT) is used to improve tumor control in patients with primary brain tumors, or brain metastasis from various primary tumors to improve tumor control. However, WBRT can lead to cognitive decline in patients. We assessed whether fractionated WBRT (fWBRT) affects spontaneous behavior of mice in automated home cages and cognition (spatial memory) using the Barnes maze.

View Article and Find Full Text PDF

Background: Cancer survivors frequently experience cognitive impairments. This systematic review assessed animal literature to identify artificial (pharmaceutical) or natural interventions (plant/endogenously-derived) to reduce treatment-related cognitive impairments.

Methods: PubMed, EMBASE, PsycINFO, Web of Science, and Scopus were searched and SYRCLE's tool was used for risk of bias assessment of the 134 included articles.

View Article and Find Full Text PDF

Purpose: This study aimed to assess health-related quality of life (HRQoL) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and to identify factors associated with this.

Methods: HRQoL was measured pre-SRS, at 3- and 6-month follow-up. Physical functioning, cognitive functioning, role functioning, and fatigue were analyzed with the EORTC QLQ-C30 questionnaire.

View Article and Find Full Text PDF
Article Synopsis
  • Many patients with malignant glioma are of working age but are often excluded from studies on cancer and work; this research aims to explore their work-related experiences and unmet needs as well as the support provided by healthcare professionals.
  • Semi-structured interviews were conducted with 22 patients diagnosed with malignant glioma and 16 healthcare professionals to gather insights on their experiences, which were then analyzed thematically.
  • The study found that patients experience significant work ability challenges due to their condition and highlighted the need for improved communication and tailored support between patients, professionals, and workplaces to better address these challenges.
View Article and Find Full Text PDF

Question: What is the diagnostic accuracy of the International Federation of Orthopaedic Manipulative Physical Therapists (IFOMPT) framework to assess the risk of vascular complications in patients seeking physiotherapy care for neck pain and/or headache?

Design: Cross-sectional diagnostic accuracy study.

Participants: One hundred and fifty patients seeking physiotherapy for neck pain and/or headache in primary care.

Methods: Nineteen physiotherapists performed the index test according to the IFOMPT framework.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1-5% of patients and can induce severe, permanent sequelae or even be fatal.

View Article and Find Full Text PDF

Background: The multidisciplinary management of patients with brain metastases consists of surgical resection, radiation treatment and systemic treatment. Tailoring and timing these treatment modalities is challenging. This study presents real-world data from consecutively treated patients and assesses the impact of all treatment strategies and their relation with survival.

View Article and Find Full Text PDF
Article Synopsis
  • A lot of young adults aged 18-39 with serious cancer are living longer because of new treatments, but they still face many daily challenges.
  • Researchers interviewed 46 young cancer patients to understand their experiences and found that many feel inferior, lonely, and uncertain about the future.
  • The study aims to improve care for these patients by focusing on their emotional struggles and how they see themselves in life.
View Article and Find Full Text PDF

Purpose: Brain metastases (BM) themselves and treatment with stereotactic radiosurgery (SRS) can influence neurocognitive functioning. This prospective study aimed to assess neurocognitive decline in patients with BM after SRS.

Methods: A neuropsychological test battery was assessed yielding ten test outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Over the past decade, cancer immunotherapy using immune checkpoint inhibitors (ICIs) has improved cancer treatment outcomes but has also led to an increase in neurological immune-related adverse events (irAEs), notably encephalitis.
  • ICI-induced encephalitis (ICI-iE) can be severe, resulting in treatment discontinuation, lasting complications, or even death, yet there is limited data on its clinical characteristics and diagnostic criteria.
  • This study gathered and analyzed 30 cases of ICI-iE alongside cases of anti-LGI1 and HSV-1 encephalitis to identify distinguishing features, aiming to enhance recognition, diagnosis, and management of ICI-iE.
View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is a deadly brain tumor with no effective standard treatment upon recurrence, prompting a need for improved strategies to manage this challenging condition.
  • The GLOW study aims to include whole genome sequencing (WGS) in the standard care for GBM patients, providing tailored treatment options based on genetic insights, in collaboration with various Dutch medical centers.
  • The study will analyze outcomes based on the percentage of patients receiving targeted therapies informed by WGS, their overall survival, and other success rates, aiming to enhance treatment protocols for those facing this aggressive cancer.
View Article and Find Full Text PDF

Aim: Immune checkpoint inhibitor-induced encephalitis (ICI-iE) is a rare but life-threatening toxicity of immune checkpoint inhibitor treatment. We aim to identify the characteristics of ICI-iE and describe factors that discriminate it from herpes simplex virus (HSV)-1 encephalitis and anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis, as two alternative entities of encephalitis.

Methods: In this retrospective multicentre cohort study, we collected patients with ICI-iE reported to the Side Effect Registry Immuno-Oncology from January 2015 to September 2021 and compared their clinical features and outcome with 46 consecutive patients with HSV-1 or anti-LGI1 encephalitis who were treated at a German neurological referral centre.

View Article and Find Full Text PDF

Background: Adolescents and young adults (AYAs, aged 18-39 years) with advanced cancer have an increased life expectancy due to improvements and refinements in cancer therapies, resulting in a growing group of AYAs living with an uncertain and/or poor cancer prognosis (UPCP). To date, no studies have examined the difficulties of health care professionals (HCPs) providing care to AYAs with a UPCP. This study aimed to understand the challenges in daily clinical practice experienced by HCPs from different disciplines who provide palliative as well as general care to AYAs with a UPCP.

View Article and Find Full Text PDF

Background: Validation of the 2016 RANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. Accordingly, this joint EORTC Brain Tumor Group and RANO effort sought to prospectively validate a revised MRI scorecard for response assessment in leptomeningeal metastasis.

Methods: Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform.

View Article and Find Full Text PDF
Article Synopsis
  • One in three individuals will face a cancer diagnosis in their lifetime, leading to an increasing focus on cancer survivorship as treatment becomes more chronic.
  • Research shows that cancer treatments, especially chemotherapy, can lead to cognitive impairments, with a growing interest in how immunotherapies may also affect cognition.
  • The article reviews current progress and stresses the need for more research on the biological causes of cognitive decline from cancer treatments, while offering recommendations for healthcare providers to support patients dealing with these cognitive challenges.
View Article and Find Full Text PDF

Objective: Clinicians are recommended to use the clinical reasoning framework developed by the International Federation of Orthopaedic Manipulative Physical Therapists (IFOMPT) to provide guidance regarding assessment of the cervical spine and potential for cervical artery dysfunction prior to manual therapy and exercise. However, the interexaminer agreement and reliability of this framework is unknown. This study aimed to estimate the interexaminer agreement and reliability of the IFOMPT framework among physical therapists in primary care.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate cognitive changes in cancer patients compared to those without cancer, focusing on patients' cognitive performance before and after their cancer diagnosis.
  • Over 2,200 participants were analyzed, with 718 having cognitive assessments; results showed that cognitive function trajectories for cancer patients were largely similar to controls, except for a slight decline in memory in cancer patients post-diagnosis.
  • The findings suggest that cancer does not significantly impact cognitive decline over time in patients who primarily received local treatments, indicating the need for future research to identify patients at higher risk for cognitive impairment.
View Article and Find Full Text PDF

Purpose: Many studies have shown that patients with non-central nervous system (CNS) cancer can have brain abnormalities, such as reduced gray matter volume and cerebral microbleeds. These abnormalities can sometimes be present even before start of treatment, suggesting a potential detrimental effect of non-CNS cancer itself on the brain. In these previous studies, psychological factors associated with a cancer diagnosis and selection bias may have influenced results.

View Article and Find Full Text PDF

Background: The EANO ESMO guidelines have proposed a classification of leptomeningeal metastases (LM) from solid cancers based on clinical, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytology presentation. MRI patterns are classified as linear, nodular, both, or neither. Type I LM is defined by positive CSF cytology (confirmed LM) whereas type II LM is defined by typical clinical and MRI signs (probable or possible LM).

View Article and Find Full Text PDF

Background: Various studies show an inverse relation between Alzheimer disease and cancer, but findings are likely to be biased by surveillance and survival bias. Plasma amyloid-β (Aβ) is defined as a preclinical feature of Alzheimer disease, with lower levels of Aβ42 being associated with a higher risk of Alzheimer disease. To get more insight into the biological link between Alzheimer disease and cancer, we investigated plasma Aβ levels in relation to the risk of cancer.

View Article and Find Full Text PDF